Clarendon Private LLC Makes New $202,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Clarendon Private LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 283 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. International Assets Investment Management LLC lifted its holdings in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $127,489,000. Icon Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after purchasing an additional 75,569 shares during the last quarter. State Street Corp boosted its holdings in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its stake in shares of Regeneron Pharmaceuticals by 40.2% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock worth $204,598,000 after acquiring an additional 55,828 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on REGN shares. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $675.79 on Friday. The company has a 50-day moving average price of $727.19 and a 200 day moving average price of $937.77. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market cap of $74.26 billion, a P/E ratio of 16.72, a PEG ratio of 1.59 and a beta of 0.10.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.